18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma

Matteo S. Carlino*, Catherine A B Saunders, Lauren E. Haydu, Alexander M. Menzies, C. Martin Curtis, Peter F. Lebowitz, Richard F. Kefford, Georgina V. Long

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Little is known about the prevalence and clinical significance of heterogeneity of positron emission tomography with 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) response. We aim to determine the prevalence, and clinicopathologic correlates of intra-patient heterogeneity of FDG-PET response in metastatic melanoma treated with dabrafenib, and to determine whether heterogeneity predicts clinical outcome. Methods: Patients with BRAF mutant metastatic melanoma and ≥2 FDG avid lesions treated on the Phase I trial of dabrafenib at a single institution (n = 23) were included. FDG-PET response was assessed by comparing baseline PET scans with scans at day 15. A heterogeneous response was defined as responding and new or metabolically progressing lesion(s) in a patient, or >10% of lesions with a stable metabolic response and responding lesions in a patient. Results: Six (26%) patients had a heterogeneous PET response. The median time to progression (TTP) was 7.4 months (95% confidence interval (CI): 6.5-8.3) for PET homogeneous responders and 3.0 months (95% CI: 0.6-5.4) for PET heterogeneous responders. There were no homogeneous non-responders. Age, BRAF mutation genotype, dose, and lactate dehydrogenase, did not predict for heterogeneity of PET response. Heterogeneity did not correlate with tumour response. Lung metastases were more likely to respond than other visceral metastatic sites. Conclusions: Heterogeneous FDG-PET responses are common in metastatic melanoma treated with dabrafenib, and heterogeneity is associated with a shorter TTP. FDG-PET heterogeneity may predict molecular heterogeneity, and FDG-PET directed biopsies may facilitate investigation into mechanisms of resistance to signal pathway inhibitors.

Original languageEnglish
Pages (from-to)395-402
Number of pages8
JournalEuropean Journal of Cancer
Volume49
Issue number2
DOIs
Publication statusPublished - Jan 2013
Externally publishedYes

Fingerprint Dive into the research topics of '<sup>18</sup>F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma'. Together they form a unique fingerprint.

Cite this